This publication has been discontinued on June 6, 2011.
Below is the updated product.
Published: April, 2011
Product code: 196747
Abstract
Ono is a research-based pure-play pharmaceutical company. For nearly three
centuries, Ono has been involved in the development of novel medicines; the
company is currently focused on the development of new treatments for diseases
of the cardiovascular, respiratory and central nervous systems, as well as
inflammatory and metabolic disorders. Ono employs over 2,400 people and is
headquartered in Osaka, Japan.
Fiscal 2009 was another difficult period for Ono. Historically, the company
markets products for niche indications, ensuring low competition and steady
sales. However, recent governmental price cuts and the implementation of
various healthcare cost containment policies have hit the company hard,
leading to declines in revenue and income. Ono is not the only Japanese
company to be impacted by these factors, several of its competitors have
entered into mergers to strengthen their position. In recent years, five major
mergers have occurred in Japan to form Dainippon Sumitomo Pharma (Dainippon
and Sumitomo Pharmaceutical), Astellas Pharma (Yamanouchi and Fujisawa),
Mitsubishi-Tanabe Pharma (Mitsubishi Pharma and Tanabe), Daiichi Sankyo
(Daiichi and Sankyo Pharmaceutical) and most recently, Kyowa Hakko Kirin
(Kyowa Hakko and Kirin Brewery). Ono has not announced any merger intentions,
which places the company in a vulnerable position.
If Ono is to emerge from this difficult period, the company will have to
rapidly overhaul its product portfolio to market products with forecasted
long-term growth. To this end, Ono established its Strategic Alliance division
in 2007. This new business segment is actively seeking collaborations around
the globe in order to expand the pipeline through licensing agreements and
bring candidate compounds to market more rapidly through research alliances.
Agreements with Merck & Co, Novartis and Astellas has seen the pipeline
bolstered by additions of Glactiv, ONO-2540 and Recalbon, which are forecast
to make strong contributions to company revenue.
This new strategic analysis report Ono: Pipeline - Products - Performance -
Potential, provides a complete and critical review of the company and
includes unique and independent assessments and forecasts of key products.
Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Table of Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Geographic Segment Performance
- Company Strategy
- R&D Strategy
- Key Agreements
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Conclusions/Outlook
- THERA PEUTIC AREA FOCU S
- R&D PIPELINE
- CAR DIOVASCULAR
- Marketed Products
- R&D Projects
- Growth Forecast
- RE SPIRAT ORY
- Marketed Products
- R&D Projects
- Growth Forecast
- INFLAMMATION
- Marketed Products
- R&D Projects
- Growth Forecast
- CNS
- Marketed Products
- R&D Projects
- ONO-4641
- Rivastach (ONO-2540)
- Growth Forecast
- METABOLISM
- Marketed Products
- R&D Projects
- Growth Forecast
- OTHERS
- Marketed Products
- R&D Projects
- CNS 7056
- ONO-3849
- ONO-4538
- ONO-7643
- ONO-7746
- ONO-8539
- APPENDIX 1 - FINANCIAL PERFORMANCE
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- Array BioPharma Inc.
- BioFocus DPI Plc.
- Dainippon Sumitomo Pharma
- Dong-A Pharmaceuticals Co., Ltd.
- Evotec
- GlaxoSmithKline
- Kyowa Hakko Kirin
- Locus Pharmaceuticals Inc.
- Medarex Inc.
- Merck & Co.
- Nissan Chemical Industries Ltd.
- Novartis
- PAION AG
- Progenics Pharmaceuticals
- Recordati
- Sapphire Therapeutics Inc.
- Santen Pharmaceutical Co Ltd.
- Tioga Pharmaceuticals
- UCB
- Xention
- APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
- APPENDIX 5 - KEY PHARMACEUTICAL
- SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint Ventures
- APPENDIX 6 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Sales by Geographic Area
- Recent Product Approvals
- Major Cardiovascular Products, 2009
- Major Respiratory Products, 2009
- Major Inflammation Products, 2009
- Major CNS Products, 2009
- Major Other Products, 2009
INDEX OF CHARTS
- Sales, Costs and Operating Income
- Sales by Geographic Area, 2009
- Sales of Top Ten Products (2004A-2014E)
- Top Selling Products, 2009
- Opalmon Sales (2004A-2014E)
- Onon Sales (2004A-2014E)
- Foipan Sales (2004A-2014E)
- Recalbon Sales (2010E-2014E)
- Kinedak Sales (2004A-2014E)
- ONO-2540 Sales (2010E-2014E)
- Glactiv Sales (2010E-2014E)
- Staybla Sales (2008A-2014E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
